Funding for this research was provided by:
efficacy and mechanism evaluation programme (12/205/56)
Received: 9 July 2021
Accepted: 17 September 2021
First Online: 29 September 2021
: All participants were in a double blind, crossover, randomised controlled trial of the oral drug bezafibrate. Ethical approval for the qualitative interview study was granted as part of the clinical trial within which it was conducted (REC ref: 15/SW/0228) on 12/11/2015. The interview data formed the basis of evaluating trial participation and are under the care of the national NHS Specialised Services Barth Syndrome Service, which is based at Bristol Royal Hospital for Children.
: As part of the informed consent procedure all participants gave permission for their interviews to recorded for analysis and if necessary relevant data could be used for publication in an anonymised form.
: The authors have no competing interests to declare.